Räddningstjänsten Östra Götaland

Räddningstjänsten Östra Götaland company information, Employees & Contact Information

Räddningstjänsten Östra Götaland är ett nytt kommunalförbundet inom området
samhällsskydd och beredskap för Linköpings och Norrköpings kommuner. Förbundet
har över 210 heltidsanställda och 130 deltidsanställda. I förbundets täckningsområde
 bor 270 000 personer och befolkningen ökar med nästan 5000 personer varje år.
 Förutom att utveckla en gemensam räddningscentral bygger vi två nya 
heltidsstationer i förbundet.

Company Details

Employees
184
Founded
-
Address
Albrektsvägen 150, Norrköping,602 39,sweden
Industry
Government Administration
NAICS
Public Administration
Justice, Public Order, and Safety Activities
Space Research and Technology
Legal Counsel and Prosecution
Correctional Institutions
Parole Offices and Probation Offices
Fire Protection
Website
rtog.se
HQ
Norrköping
Looking for a particular Räddningstjänsten Östra Götaland employee's phone or email?

Räddningstjänsten Östra Götaland Questions

News

RNI Omission in ypN0 Breast Cancer-NRG B‑51/RTOG 1304 trial - Oncodaily

RNI Omission in ypN0 Breast Cancer-NRG B‑51/RTOG 1304 trial Oncodaily

Nina Niu Sanford: RTOG 1112 is finally out - Oncodaily

Nina Niu Sanford: RTOG 1112 is finally out Oncodaily

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 - ASCO Publications

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 ASCO Publications

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial - The Lancet

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial The Lancet

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer - The New England Journal of Medicine

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer The New England Journal of Medicine

RTOG Foundation establishes four new committees; names committee leaders - The Cancer Letter

RTOG Foundation establishes four new committees; names committee leaders The Cancer Letter

RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer - Medscape

RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer Medscape

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial - The Lancet

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial The Lancet

Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer - The New England Journal of Medicine

Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer The New England Journal of Medicine

Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802 - ASCO Publications

Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802 ASCO Publications

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial - The Lancet

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial The Lancet

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 - ASCO Publications

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 ASCO Publications

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial - The Lancet

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial The Lancet

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phas - The Lancet

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phas The Lancet

Top Räddningstjänsten Östra Götaland Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant